All
FDA OKs Investigational New Drug Application for VS-7375 in Solid Tumors
Verastem will launch a U.S. phase 1/2a trial of oral KRAS G12D inhibitor VS-7375 after FDA IND clearance, with data to be presented at ASCO 2025.
Crafting an Individual Treatment Plan for Patients With Prostate Cancer
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Commitment to Patients Is Driven by a Lasting Promise
Mikela Pettigrew, B.S.N., RN, OCN,, exemplifies extraordinary compassion and dedication. Every day, she fulfills a promise she made as a young caregiver.
Understanding the FDA Imfinzi Combo Approval for Bladder Cancer Care
Dr. Matthew Galsky highlights the impact of Imfinzi’s adjuvant approval for patients with muscle-invasive bladder cancer following cystectomy and chemo.
New Options for ER+ Breast Cancer Spotlighted at Patient Event
Dr. Brian Czerniecki, of Moffitt Cancer Center, led a CURE Educated Patient® Updates in Metastatic Breast Cancer event, and provided subsequent updates.
A Digital Detox for the Soul with Lynch Syndrome
Unplugging from digital noise helped me find peace, clarity and room for growth during a season of emotional and mental renewal.
Decipher Prostate Test Now Available for Metastatic Prostate Cancer
Decipher Prostate Metastatic Genomic Classifier is now available for patients with metastatic prostate cancer.
Evorpacept With Keytruda Did Not Elicit Responses in Head and Neck Cancer
In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 and ASPEN trials.
ctDNA Clearance Linked to Improved Survival in Oncogene-Driven NSCLC
Among patients with oncogene-driven advanced NSCLC who were treated with TKIs, ctDNA clearance was associated with improved survival end points.
The Fearless Patient Advocate
Kathleen Coughlin, although small in stature, is often referred to as the “Bulldozer.”
Working to Address Unmet Medical Needs in MPNs
CURE spoke with John Crispino, the director of the division of experimental hematology at St. Jude Children’s Research Hospital.
First Patient Enrolled in ARID II Trial for Prostate Cancer Treatment
The first patient has been enrolled in the ARID II trial evaluating Voro Urologic Scaffold to improve continence after prostate cancer surgery.
Taking Charge of My Care and Advocacy Following a Cancer Diagnosis
After a long battle with illness and seeking many specialists, I emphasize the need to self-advocate for ongoing care following my cancer diagnosis.
FDA Approves Penpulimab-kcqx For Nasopharyngeal Carcinoma
The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma.
Dose-Limiting Toxicity Observation Phase Completed in CRS Trial for Lymphoma
In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group's dose-limiting toxicity observation period was successfully completed.
Early Symptoms, Risk Factors and Treatment Options for Esophageal Cancer
In a Q&A, Dr. Nataliya Uboha discussed how difficulty swallowing may signal esophageal cancer, treatment options and ongoing research to improve patient outcomes.
Optune Lua Receives CE Mark in Europe for Metastatic NSCLC
Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.
How to Best Navigate a Diagnosis of Lung and Head and Neck Cancer
Dr. Douglas Reznick shares advice for patients with lung or head and neck cancer who may feel overwhelmed by their diagnosis.
Joy Anderson Reflects on Her Diagnosis of a Rare Blood Cancer
A push for answers led to a rare blood disorder diagnosis after Joy’s symptoms were initially dismissed.
The Burst of Spring: Reflection for Those Living with Cancer
As spring arrives, I embrace the season’s renewal, reflecting on my journey with cancer and the freedom I’ll feel when I stop my treatment. Life is a gift.
Ivonescimab Plus Chemo May Slow Advanced NSCLC Progression
In patients with advanced squamous non–small cell lung cancer, ivonescimab plus chemo was associated with progression-free survival results.
FDA Grants Breakthrough Status to CAR-T Therapy for Pediatric Brain Tumor
The FDA granted breakthrough therapy designation to an autologous CAR-T cell therapy for pediatric patients with diffuse intrinsic pontine glioma.
First Patient Dosed with AP402 in a Trial for HER2 Advanced Tumors
Advocacy and ‘Radiating Valor’ Have a Transformative Impact
Air Matters: Radon and the Environment
Odronextamab Elicits Responses in Some With Lymphoma Following CAR-T
LCI Launches Screening Saves Program
Overcoming Barriers to Emotional and Physical Support in Cancer Care
An expert sat down to discuss the emotional and physical barriers patients may face when seeking support for fear of cancer progression.
Support Patient Access and Education with the End Brain Cancer Initiative for GiveBIG 2025
People can help EBCI reach their goal of $20,000 dollars raised for GiveBIG 2025 by giving at endbraincancer.org/donate.
Remission is Not a Cure for Follicular Lymphoma, or Any Cancer
It’s spring, a time for new beginnings following a cancer diagnosis; however, I have an ongoing issue that I can’t dismiss.
